Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457 · View on ClinicalTrials.gov ↗
Study Summary
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug. A sub-study of approximately 60 adult patients who are participating in the B7981032 study will be conducted at select sites in the US, Australia and Canada. The sub-study will evaluate the immune response to tetanus and meningococcal vaccines in patients who have received a minimum of 6 months of 50 mg PF-06651600.
Conditions Studied
Interventions
- DRUG PF-06651600
- BIOLOGICAL Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
- BIOLOGICAL Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Study Locations (20)
California
- Mosaic Dermatology — Beverly Hills
- Univ of California, Irvine, Dermatology Clinical Research Center — Irvine
- Dermatology Specialists Inc. — Murrieta
- University of California, San Francisco — San Francisco
- Kaiser Permanente Clinical Trials Unit — San Francisco
- Southern California Dermatology, Inc. — Santa Ana
District of Columbia
- Medstar Georgetown University Hospital - Department of Otolaryngology — Washington D.C.
- Medstar Georgetown University Hospital-Dept of Otolaryngology — Washington D.C.
- MedStar Washington Hospital Center — Washington D.C.
- Medstar Georgetown University Hospital - Department of Pediatrics — Washington D.C.
Alabama
- The University of Alabama at Birmingham Hosptial Outreach Lab — Birmingham
- The University of Alabama at Birmingham — Birmingham
- The University of Alabama at Birmingham, Department of Dermatology — Birmingham
Colorado
- University of Colorado Anschutz Medical Campus — Aurora
- University of Colorado Hospital Clinical and Translational Research Center — Aurora
- University of Colorado Hospital Outpatient Pavilion — Aurora
Florida
- Siperstein Dermatology Group — Boynton Beach
- Park Avenue Dermatology — Orange Park
- ForCare Clinical Research — Tampa
Connecticut
- Yale School of Medicine, Yale Center for Clinical Investigations — New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,052 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04006457
The ClinicalTrials.gov registry entry for NCT04006457 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,052 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 3 interventions — of which PF-06651600 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04006457 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, District of Columbia, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04006457 about?
NCT04006457 is a clinical study titled "Long-Term PF-06651600 for the Treatment of Alopecia Areata". This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have ...
What is the current status of trial NCT04006457?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,052 participants. The study started on 2019-07-18. Estimated completion is 2026-03-01.
What conditions does trial NCT04006457 study?
This clinical trial studies the following conditions: Alopecia Areata. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04006457?
The interventions under investigation include: PF-06651600 (DRUG), Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine (BIOLOGICAL), Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04006457?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04006457 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.